Polypeptide for removing iron and free radicals in brain and preparation method and application thereof

Abstract

The present invention provides comprises a polypeptide for removing iron and free radicals in brain and a preparation method and application thereof, the preparation method comprises combination of amino acids capable of binding iron in polypeptide A beta 42 according to predetermined times of repetition to obtain the polypeptide. The polypeptide obtained by the method has larger solubility, can effectively chelate iron ions in cerebrospinal fluid of patients with Alzheimer's disease, and can effectively reduce the free radicals.

Description

technical field [0001] The invention relates to the technical field of polypeptide synthesis, in particular to a polypeptide for reducing iron and removing free radicals in the brain, a preparation method and an application. Background technique [0002] Alzheimer's Disease (Alzheimer's Disease, Alzheimer's disease) is a kind of neurodegenerative disease, because a large number of necrosis of neurons, causes brain atrophy, thus can cause loss of memory, mental disorder, language disorder and personality variation; The family brings great troubles and burdens, the cause of the disease is still unclear, and there is still no effective treatment. [0003] Studies have shown that the brain iron content of Alzheimer's patients is about 35% higher than that of normal brains. During the process of metabolic life activities, organisms will continuously generate some oxidative active substances, such as H 2 o 2 etc., can be compared with Fe 2+ The ions react to generate free radic...

AI Technical Summary

Problems solved by technology

[0002] Alzheimer's Disease (Alzheimer's Disease, Alzheimer's disease) is a kind of neurodegenerative disease, because a large number of necrosis of neurons, causes brain atrophy, thus can cause loss of memory, mental disorder, language disorder and personality variation; The family brings great troubles and burdens, the cause of the disease is still unclear, and there is still no effective treatment

[0003] Studies have shown that the brain iron content of Alzheimer's patients is about 35% higher than that of normal brains. During the process of metabolic life activities, organisms will continuously generate some oxidative active substances, such as H 2 o 2 etc., can be compared with Fe 2+ The ions react to generate free radicals, and the generated free radicals can further interact with biological macromolecules in the body, destroying lipids and proteins in tissues and cells, resulting in cell damage and tissue necrosis; therefore, removing redundant iron in the brain , is a direction for the treatment of Alzheimer's disease. Some people have used oral drugs such as deferoxamine and deferaros to remove excessive iron in the blood and brain to relieve symptoms, but taking these drugs for a long time can easily cause kidney failure and blood diseases , with serious side effects

[0004] In the prior art, Aβ42 is a polypeptide containing 42 amino acid residues secreted by amyloid precursor protein-APP fragmentation in the brain, wherein tyrosine (Tyr, Y), glutamic acid (Glu, E) , aspartic acid (Asp, D), and methionine (Met, M) residues can combine with iron to deposit, reduce the concentration of iron in the solution, and reduce free radicals; however, the natural Aβ42 polypeptide can bind iron Amino acid residues only account for 1 / 3 of the total amino acid sequence, and the solubility is small, so it is difficult to be used in the preparation of drugs for the treatment of Alzheimer's disease

Images